Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration.
Stephen J FreedlandRickard SandinJanvi SahBirol EmirQiao MuAnna RatiuAgnes HongLucile SerfassScott T TagawaPublished in: Cancer medicine (2021)
Most patients with mCSPC initiating ADT received ADT-only or ADT + NSAA, despite the emergence of docetaxel and novel hormonal therapies. Even in the most recent period (2017 to early 2018), only 24% of men received intensified therapy with agents known to prolong survival versus ADT-only. These data in real-world clinical practice suggest substantial room for improved outcomes in patients with mCSPC.
Keyphrases
- prostate cancer
- clinical practice
- healthcare
- public health
- small cell lung cancer
- squamous cell carcinoma
- free survival
- radical prostatectomy
- mental health
- electronic health record
- type diabetes
- stem cells
- health information
- machine learning
- locally advanced
- adipose tissue
- mesenchymal stem cells
- polycystic ovary syndrome
- replacement therapy
- metabolic syndrome
- radiation therapy
- rectal cancer
- smoking cessation